SG11201503308XA - PRODUCTION OF RECOMBINANT VACCINE IN <i>E. COLI</i> BY ENZYMATIC CONJUGATION - Google Patents
PRODUCTION OF RECOMBINANT VACCINE IN <i>E. COLI</i> BY ENZYMATIC CONJUGATIONInfo
- Publication number
- SG11201503308XA SG11201503308XA SG11201503308XA SG11201503308XA SG11201503308XA SG 11201503308X A SG11201503308X A SG 11201503308XA SG 11201503308X A SG11201503308X A SG 11201503308XA SG 11201503308X A SG11201503308X A SG 11201503308XA SG 11201503308X A SG11201503308X A SG 11201503308XA
- Authority
- SG
- Singapore
- Prior art keywords
- coli
- production
- recombinant vaccine
- enzymatic conjugation
- conjugation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723408P | 2012-11-07 | 2012-11-07 | |
| PCT/EP2013/073266 WO2014072405A1 (fr) | 2012-11-07 | 2013-11-07 | Production d'un vaccin recombinant dans e. coli par conjugaison enzymatique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201503308XA true SG11201503308XA (en) | 2015-05-28 |
Family
ID=49552366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201503308XA SG11201503308XA (en) | 2012-11-07 | 2013-11-07 | PRODUCTION OF RECOMBINANT VACCINE IN <i>E. COLI</i> BY ENZYMATIC CONJUGATION |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20150273043A1 (fr) |
| EP (3) | EP3444352B1 (fr) |
| JP (2) | JP6412875B2 (fr) |
| KR (1) | KR20150079964A (fr) |
| CN (1) | CN105008539B (fr) |
| AU (2) | AU2013343520B2 (fr) |
| BR (1) | BR112015010283A8 (fr) |
| CA (2) | CA3125293A1 (fr) |
| EA (1) | EA201590705A1 (fr) |
| ES (3) | ES2882282T3 (fr) |
| IL (1) | IL238586A0 (fr) |
| MX (1) | MX366912B (fr) |
| SG (1) | SG11201503308XA (fr) |
| TR (1) | TR201903066T4 (fr) |
| WO (1) | WO2014072405A1 (fr) |
| ZA (1) | ZA201503097B (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2501406T (pt) * | 2009-11-19 | 2018-02-21 | Glaxosmithkline Biologicals Sa | Sistema de biossíntese que produz polissacáridos imunogénicos em células procariotas |
| BR112016007727A8 (pt) | 2013-10-11 | 2018-01-30 | Glycovaxyn Ag | célula hospedeira, e, método para produzir uma proteína n-glicosilada. |
| EP3131577B1 (fr) * | 2014-04-17 | 2020-04-22 | GlaxoSmithKline Biologicals S.A. | Cellules hôtes modifiées et leurs utilisations |
| ES2793023T3 (es) | 2014-08-08 | 2020-11-12 | Glaxosmithkline Biologicals Sa | Células huésped modificadas y oligosacáridos híbridos para su uso en producción de bioconjugados |
| WO2016134485A1 (fr) | 2015-02-26 | 2016-09-01 | Vaxalta Inc. | O-oligosaccharyltransférase d'acinetobacter et ses utilisations |
| GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
| GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
| CN105963691B (zh) * | 2016-07-03 | 2020-05-01 | 查文娟 | 一种肺炎链球菌疫苗 |
| CN106929573B (zh) * | 2017-02-21 | 2020-06-09 | 南开大学 | 对嗜肺军团菌O12型的wzm和wecA基因特异的核苷酸序列及其应用 |
| GB201712678D0 (en) | 2017-08-07 | 2017-09-20 | Glaxosmithkline Biologicals Sa | Process for the manipulation of nucleic acids |
| WO2019043245A1 (fr) * | 2017-09-04 | 2019-03-07 | London School Of Hygiene And Tropical Medicine | Cellules microbiennes exprimant des sérotypes streptococciques |
| US11235046B2 (en) | 2017-11-04 | 2022-02-01 | Nevada Research & Innovation Corporation | Immunogenic conjugates and methods of use thereof |
| GB201721582D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
| GB201721576D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
| WO2019241672A2 (fr) * | 2018-06-16 | 2019-12-19 | Vaxnewmo Llc | Variants de piline comp glycosylés, leurs procédés de fabrication et leurs utilisations |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| EP3650044A1 (fr) * | 2018-11-06 | 2020-05-13 | ETH Zürich | Vaccins antiglycane |
| US20220088211A1 (en) * | 2018-12-21 | 2022-03-24 | Vaxnewmo Llc | O-linked glycosylation recognition motifs |
| PL3942028T3 (pl) * | 2019-03-18 | 2023-10-23 | Janssen Pharmaceuticals, Inc. | Sposób wytwarzania biokoniugatów polisacharydów antygenu O E. coli, zawierające je kompozycje oraz sposoby ich zastosowania |
| EP3770269A1 (fr) | 2019-07-23 | 2021-01-27 | GlaxoSmithKline Biologicals S.A. | Quantification de glycosylation de bioconjugués |
| CN111518738B (zh) * | 2020-05-08 | 2022-02-08 | 徐州海润生物科技有限公司 | 重组卡介苗及其制备方法和应用 |
| EP4171625A2 (fr) | 2020-06-25 | 2023-05-03 | GlaxoSmithKline Biologicals SA | Vaccin |
| EP4452308A1 (fr) | 2021-12-22 | 2024-10-30 | GlaxoSmithKline Biologicals S.A. | Vaccin |
| GB202302579D0 (en) | 2023-02-23 | 2023-04-12 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995031548A1 (fr) * | 1994-05-16 | 1995-11-23 | The Uab Research Foundation | Genes de polysaccharide capsulaire de streptococcus pneumoniaeet leurs regions d'encadrement |
| US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
| US7541043B2 (en) | 2002-01-16 | 2009-06-02 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine for protection against Shigella sonnei disease |
| WO2003074687A1 (fr) | 2002-03-07 | 2003-09-12 | Eidgenössische Technische Hochschule Zürich | Systeme et procede de fabrication de proteines glycosylees de recombinaison dans un hote procaryotique |
| EP2853600B1 (fr) | 2005-05-11 | 2018-09-19 | ETH Zürich | Proteines N-glycosylées de recombinaison produites a partir de cellules procaryotes |
| CN101983070B (zh) | 2008-02-20 | 2016-03-30 | 格林考瓦因有限公司 | 由来源于原核细胞的重组n-糖基化蛋白制备生物共轭物 |
| EP2411039A4 (fr) * | 2009-03-23 | 2015-05-06 | Brigham & Womens Hospital | Vaccins glycoconjugués |
| KR20120085240A (ko) | 2009-07-17 | 2012-07-31 | 오션 하베스트 테크놀로지 (캐나다) 아이엔씨. | 어류 사료에서 합성 첨가제를 대체하는 천연 및 지속 가능 해조류 배합 |
| PT2566507T (pt) | 2010-05-06 | 2018-02-06 | Glaxosmithkline Biologicals Sa | Vacinas de bioconjugado de bactérias gram-positivas capsulares |
| ES2905107T3 (es) * | 2012-10-12 | 2022-04-07 | Glaxosmithkline Biologicals Sa | Procedimientos de modificación de células hospedadoras |
-
2013
- 2013-11-07 AU AU2013343520A patent/AU2013343520B2/en active Active
- 2013-11-07 EP EP18198665.4A patent/EP3444352B1/fr active Active
- 2013-11-07 ES ES18211761T patent/ES2882282T3/es active Active
- 2013-11-07 CA CA3125293A patent/CA3125293A1/fr active Pending
- 2013-11-07 WO PCT/EP2013/073266 patent/WO2014072405A1/fr active Application Filing
- 2013-11-07 US US14/440,311 patent/US20150273043A1/en not_active Abandoned
- 2013-11-07 KR KR1020157014830A patent/KR20150079964A/ko not_active Application Discontinuation
- 2013-11-07 EA EA201590705A patent/EA201590705A1/ru unknown
- 2013-11-07 CA CA2889767A patent/CA2889767C/fr active Active
- 2013-11-07 EP EP13788753.5A patent/EP2917351B1/fr active Active
- 2013-11-07 CN CN201380069524.XA patent/CN105008539B/zh active Active
- 2013-11-07 ES ES13788753T patent/ES2713166T3/es active Active
- 2013-11-07 ES ES18198665T patent/ES2848774T3/es active Active
- 2013-11-07 SG SG11201503308XA patent/SG11201503308XA/en unknown
- 2013-11-07 BR BR112015010283A patent/BR112015010283A8/pt not_active Application Discontinuation
- 2013-11-07 MX MX2015005797A patent/MX366912B/es active IP Right Grant
- 2013-11-07 EP EP18211761.4A patent/EP3508579B1/fr active Active
- 2013-11-07 TR TR2019/03066T patent/TR201903066T4/tr unknown
- 2013-11-07 JP JP2015541130A patent/JP6412875B2/ja active Active
-
2015
- 2015-05-03 IL IL238586A patent/IL238586A0/en unknown
- 2015-05-06 ZA ZA2015/03097A patent/ZA201503097B/en unknown
-
2017
- 2017-12-20 AU AU2017279688A patent/AU2017279688B2/en active Active
-
2018
- 2018-07-13 US US16/034,906 patent/US10973901B2/en active Active
- 2018-10-01 JP JP2018186302A patent/JP6833785B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201503308XA (en) | PRODUCTION OF RECOMBINANT VACCINE IN <i>E. COLI</i> BY ENZYMATIC CONJUGATION | |
| IL280949B (en) | Ph20 polypeptide variants, formulations and uses thereof | |
| HK1231412A1 (zh) | 免疫原性組合物 | |
| EP2807799B8 (fr) | Messagerie de repli | |
| EP2818543A4 (fr) | Bacille, hyaluronidase et leurs applications | |
| EP2864470A4 (fr) | Microorganismes recombinants produisant du biodiesel | |
| PL2748300T3 (pl) | Szczepy Bacillus wytwarzające enzym | |
| SG11201400432VA (en) | Polypeptide vaccine | |
| SG11201502010TA (en) | NOVEL RECOMBINANT <i>BORDETELLA</i> STRAINS | |
| HUE040914T4 (hu) | Immunogén készítmény | |
| HK1212133A1 (en) | Enhancing aqm to combat wireless losses aqm | |
| HK1199060A1 (en) | Recombinant escherichia coli strains | |
| FR2988733B1 (fr) | Microorganisme recombinant | |
| SG11201405100VA (en) | Improvements relating to valves. | |
| HRP20181115T1 (hr) | Proizvodnja izopropanola poboljšanim rekombinantnim sojevima | |
| EP2771461A4 (fr) | Souches hôtes eucaryotes inférieures génétiquement modifiées pour une expression protéique recombinante | |
| HK1211323A1 (en) | Dual enzymatic amplification | |
| Reicher et al. | Culture of Shock | |
| AU2013348363B2 (en) | Terminally modified RNA | |
| AU2012904907A0 (en) | Toughened thermosets | |
| AU2012902593A0 (en) | Improved Recombinant Viruses | |
| GB201115906D0 (en) | Escherichia coli vaccine combination | |
| GB201204968D0 (en) | Immunogenic composition | |
| GB201204851D0 (en) | Immunogenic composition | |
| AU2010086V (en) | Zaipava Prunus persica var. nucipersica |